Stay updated with the latest stock market news and insights
Weekly insights + SMS alerts
Teladoc Health, Inc. (NYSE:TDOC) said Wednesday it is adding two artificial intelligence-powered capabilities to its Solo platform as the virtual care provider looks to help hospitals streamline clinical workflows.
The new tools, SoloVitals and SoloScribe, aim to give care teams faster access to patient information while reducing the need for separate technology platforms.
SoloVitals allows clinicians to measure a patient's heart rate and respiration rate without physical contact.
The technology uses the camera on a smartphone or tablet to analyze subtle changes in facial skin color. It relies on remote photoplethysmography, or rPPG, to generate vital-sign measurements during virtual consultations.
Teladoc said the clinically validated technology can help clinicians make more informed decisions during remote visits.
SoloVitals is currently available to select customers through a private preview. Teladoc expects a broader release in December 2026.
Meanwhile, SoloScribe uses ambient AI to create structured clinical notes during virtual appointments.
The tool generates a templated summary that can be transferred into a patient's electronic health record. It supports direct-to-patient consultations and visits conducted through telemedicine devices.
Teladoc said SoloScribe can reduce administrative work and allow clinicians to focus more attention on patients. The service is now generally available.
Both tools are built directly into the Solo platform. Teladoc said this approach can help hospitals adopt AI without adding more standalone systems or infrastructure.
Teladoc's Solo technology is installed at more than 15,000 care locations worldwide.
The platform also integrates with electronic health record systems from Epic and Oracle Corporation's (NYSE:ORCL) Oracle Health using HL7 and FHIR standards.
Teladoc said the expanded platform is designed to help health systems scale virtual care while simplifying technology management for clinical teams.
Teladoc Health stock is trading modestly higher during Wednesday's premarket session, outperforming a softer broader market. Meanwhile, Nasdaq futures fell 0.65%, while S&P 500 futures slipped 0.33%.
The stock's early gain appears to reflect positioning near key technical levels. The stock has struggled over the past year.
Teladoc remains in a longer-term downtrend. The stock has fallen 31.06% over the past 12 months and continues to trade below its major moving averages.
At $5.79, the stock is about 3.8% below its 20-day simple moving average of $6.08. It is also 9.8% below its 50-day SMA of $6.48 and 10.7% below its 200-day SMA of $6.55.
The moving-average structure also remains bearish. The 20-day SMA is below the 50-day SMA, while the 50-day SMA remains below the 200-day SMA.
Momentum indicators also point to caution. The MACD remains below its signal line, while the histogram is negative. That suggests buying momentum has weakened.
Key resistance sits near $6.50, close to the 50-day exponential moving average. Support is around $5.
The stock carries a Buy consensus rating with an average price forecast of $8.88.
Citigroup maintained a Neutral rating on Aug. 3 and lowered its price forecast to $7.50. Canaccord Genuity maintained a Buy rating on July 30 and lowered its price forecast to $10. Evercore ISI Group maintained an In-Line rating the same day and cut its price forecast to $7.50.
Teladoc has a weak Momentum score of 8.96 on the Edge scorecard.
The reading reflects the stock's weak price trend and its position below key moving averages.
For the technical picture to improve, Teladoc would likely need to reclaim the $6.50 area and hold above it.
KraneShares Man Buyout Beta Index ETF (NYSE:BUYO) has a 0.99% weighting in Teladoc.
Fund inflows or outflows can therefore contribute to buying or selling pressure in Teladoc shares.
TDOC Stock Price Activity: Teladoc Health shares were up 0.35% at $5.79 during premarket trading on Wednesday, according to market data.
Real-time alerts on price moves, news, and trading opportunities.
Join 20,000+ investors. No spam, ever.
